KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Depreciation & Amortization (CF): 2016-2024

Historic Depreciation & Amortization (CF) for Moderna (MRNA) over the last 9 years, with Dec 2024 value amounting to $189.0 million.

  • Moderna's Depreciation & Amortization (CF) changed negligibly% to $52.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $208.0 million, marking a year-over-year decrease of 37.16%. This contributed to the annual value of $189.0 million for FY2024, which is 69.57% down from last year.
  • Moderna's Depreciation & Amortization (CF) amounted to $189.0 million in FY2024, which was down 69.57% from $621.0 million recorded in FY2023.
  • Moderna's 5-year Depreciation & Amortization (CF) high stood at $621.0 million for FY2023, and its period low was $31.0 million during FY2020.
  • In the last 3 years, Moderna's Depreciation & Amortization (CF) had a median value of $348.0 million in 2022 and averaged $386.0 million.
  • Per our database at Business Quant, Moderna's Depreciation & Amortization (CF) spiked by 648.39% in 2021 and then tumbled by 69.57% in 2024.
  • Yearly analysis of 5 years shows Moderna's Depreciation & Amortization (CF) stood at $31.0 million in 2020, then skyrocketed by 648.39% to $232.0 million in 2021, then skyrocketed by 50.00% to $348.0 million in 2022, then skyrocketed by 78.45% to $621.0 million in 2023, then plummeted by 69.57% to $189.0 million in 2024.